Symbols

SERA

Sera Prognostics·NASDAQ

--(--)

SERA fundamentals

SERA Q4 2025 Earnings

Sera Prognostics (SERA) released its earnings on Mar 18, 2026: revenue was 10.00K (YoY -58.33%), missed estimates; EPS was -0.16 (YoY +36.00%), beat estimates.

Revenue / YoY

10.00K

-58.33%

EPS / YoY

-0.16

+36.00%

Report date

Mar 18, 2026

SERA Earnings Call Summary for Q4,2025

Breakthrough Clinical Evidence: PRIME study demonstrates 56% reduction in extreme preterm births, validating biomarker-based preterm prediction.
Rapid Commercial Expansion: 13 states engaged in 2025, targeting 15-17 states by year-end with 5-7 active Partner Programs.
Financial Strength: $95.8M cash runway through 2028, disciplined spending with no immediate capital needs.
Payer Value Proposition: 20% NICU utilization reduction positions PreTRM as cost-saving solution for Medicaid and commercial plans.

Earnings

EPS

Revenue

Revenue & Expenses

SERA has released its 2025 Q4 earnings report, with revenue of 10.00K, reflecting a YoY change of -58.33%, and net profit of -7.88M, showing a YoY change of 8.14%. The Sankey diagram below clearly presents SERA's revenue sources and cost distribution.

Key Indicators

Sera Prognostics (SERA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Sera Prognostics (SERA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Sera Prognostics (SERA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Sera Prognostics (SERA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown